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Clinical implications for patients treated
inappropriately for community-acquired
pneumonia in the emergency department
Scott T Micek1, Adam Lang2, Brian M Fuller3, Nicholas B Hampton4 and Marin H Kollef5*

Abstract
Background: Community-acquired pneumonia (CAP) is one of the most common infections presenting to the
emergency department (ED). Increasingly, antibiotic resistant bacteria have been identified as causative pathogens
in patients treated for CAP, especially in patients with healthcare exposure risk factors.
Methods: We retrospectively identified adult subjects treated for CAP in the ED requiring hospital admission
(January 2003-December 2011). Inappropriate antibiotic treatment, defined as an antibiotic regimen that lacked
in vitro activity against the isolated pathogen, served as the primary end point. Information regarding demographics,
severity of illness, comorbidities, and antibiotic treatment was recorded. Logistic regression was used to determine
factors independently associated with inappropriate treatment.
Results: The initial cohort included 259 patients, 72 (27.8%) receiving inappropriate antibiotic treatment. There was no
difference in hospital mortality between patients receiving inappropriate and appropriate treatment (8.3% vs. 7.0%;
p = 0.702). Hospital length of stay (10.3 ± 12.0 days vs. 7.0 ± 8.9 days; p = 0.017) and 30-day readmission (23.6% vs.
12.3%; p = 0.024) were greater among patients receiving inappropriate treatment. Three variables were independently
associated with inappropriate treatment: admission from long-term care (AOR, 9.05; 95% CI, 3.93-20.84), antibiotic
exposure in the previous 30 days (AOR, 1.85; 95% CI, 1.35-2.52), and chronic obstructive pulmonary disease (AOR, 2.05;
95% CI, 1.52-2.78).
Conclusion: Inappropriate antibiotic treatment of presumed CAP in the ED negatively impacts patient outcome and
readmission rate. Knowledge of risk factors associated with inappropriate antibiotic treatment of presumed CAP could
advance the management of patients with pneumonia presenting to the ED and potentially improve patient outcomes.
Keywords: Pneumonia, Antibiotics, Resistant pathogens, Outcomes

Background
Community-acquired pneumonia (CAP) is an important
infection globally, and accounts for significant morbidity,
mortality, and economic burden [1-5]. Mortality may be
as high as 14% overall, whereas for the elderly, mortality
reaches greater than 50% within 5 years [1,5]. Treatment
of CAP is potentially compromised by the rapid emergence of bacterial resistance to the most commonly
prescribed antibiotics, including beta-lactams, macrolides, and fluoroquinolones [6]. Even multidrug-resistant
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(MDR) strains (commonly defined as resistance to three
or more of the commonly used classes of agents) are
emerging [6]. Traditionally, pneumonia developing in
recently hospitalized patients or those residing in longterm care facilities, nursing homes, or undergoing dialysis,
has been classified and treated as CAP. However, a new
pneumonia classification, distinct from CAP —healthcareassociated pneumonia (HCAP)—has been introduced to
address patients outside of the hospital at risk of infection
with MDR pathogens [7]. The 2005 American Thoracic
Society/Infectious Disease Society of America (ATS/IDSA)
guidelines also recognized HCAP as a new category of
pneumonia [8].
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Patients with HCAP risk factors are at increased risk
of infection with MDR pathogens [9-16]. Physicians
should be aware that microbiological features and clinical outcomes of patients with HCAP are more similar
to patients with hospital-acquired pneumonia (HAP)
than those with traditional CAP [9]. A critical disparity
appears to be the more frequent administration of inappropriate antibiotic treatment in patients with HCAP
compared to those with CAP, secondary to a higher incidence of antibiotic-resistant pathogens in HCAP [13].
However, factors associated with inappropriate antibiotic
administration in the emergency department (ED), and
the short- and long-term impact of inappropriate therapy has not been well studied. Therefore, we performed
an investigation to assess the incidence of inappropriate
initial antibiotic treatment of hospitalized patients with
presumed CAP presenting to the ED. We also aimed to
assess risk factors associated with inappropriate antibiotic treatment and its relationship to other clinical
outcomes.

Methods
Study overview and subjects

We retrospectively identified all hospitalized adult
(age >18 years) patients diagnosed and treated for
culture-positive CAP in the ED between January 1,
2003 and December 31, 2011. Presumed CAP was defined as a new or progressive radiographic infiltrate
plus one of the following: temperature greater than
38.3°C, WBC greater than 10,000/μL, or purulent tracheal secretions. One investigator (MHK), blinded to
the clinical and microbiologic information adjudicated
the chest imaging. To be included, patients had to be
treated in the ED with a CAP antimicrobial regimen
that included at our institution ceftriaxone plus azithromycin or moxifloxacin. Identification of pathogens
was based on the results of cultures obtained in the ED
from blood, pleural fluid, sputum, or the lower airways.
A positive urinary antigen for Legionella pneumophilia
serogroup 1 was used to document infection with this
pathogen. The Washington University School of Medicine
Human Studies Committee approved the study.
Endpoints and covariates

Patients receiving inappropriate therapy, defined as an
antibiotic regimen that lacked in vitro activity against
the isolated pathogen, were compared to those receiving
appropriate antibiotic therapy. Covariates of interest
included patient demographics, severity of illness, the
Charlson score, and antibiotic treatment. Demographic
factors included age, gender, and race. Comorbidities potentially influencing the isolated pathogen included residence in a long-term care facility, hospitalization in the
last 90 days, receipt of antimicrobials in the last 30 days,

Page 2 of 8

end-stage renal disease requiring hemodialysis, and immunosuppression. Immunosuppression was defined as the
presence of the human immunodeficiency virus (HIV),
active malignancy undergoing chemotherapy, or treatment
with immunosuppressants (i.e., 10 mg prednisone or
equivalent daily for at least 30 days or alternate agents).
Disease severity was assessed with the CURB-65 score,
along with the need for either intensive care unit (ICU)
admission or mechanical ventilation [17]. Infectionrelated variables included the presence of bacteremia
complicating the pneumonia, and the presence of polymicrobial infection. We classified the initial antibiotic
regimen as appropriate if the antibiotic regimen demonstrated in vitro activity against the pathogen(s) isolated
and was administered within 6 hours of presentation.
Statistics

We completed univariate analyses with either the Fisher’s
exact test or Student’s t-test as appropriate. Continuous,
non-parametrically distributed data was compared via the
Mann–Whitney U test. All analyses were two tailed, and a
p value of < 0.05 was statistically significant. Logistic regression was used to determine independent factors associated
with inappropriate treatment. Variables significant at
p < 0.10 in univariate analyses were entered into the model.
To arrive at the most parsimonious model we utilized a
step-wise backward elimination approach. Co-linearity was
explored with correlation matrices. Adjusted odds ratios
(AORs) and ninety-five percent confidence intervals (CIs)
are reported where appropriate. The model’s goodness-offit was assessed via calculation of the R2 value and the
Hosmer-Lemeshow c-statistic. All analyses were performed
with SPSS 11.0 (SPSS, Chicago, IL).

Results
During the study period there were 1367 patients with
culture-positive bacterial pneumonia admitted from the
ED. Among these 1108 (81.5%) were diagnosed and
treated for presumed HCAP, received initial treatment
with broad-spectrum antibiotics and excluded from analysis. Of the 259 patients diagnosed and treated for CAP,
187 (72.2%) received appropriate antibiotic treatment
and 72 (27.8%) received inappropriate treatment (Figure 1).
Overall hospital mortality was 7.3% and 30-day hospital readmission was 15.4%. The average hospital length of stay
was 7.9 days (median 5 days).
Table 1 shows the characteristics of patients receiving
appropriate and inappropriate antibiotic treatment. There
were no differences in demographics or severity of illness
between groups. There was a trend towards greater ICU
admission for patients receiving inappropriate treatment
(p = 0.052).
With respect to infection-related characteristics, patients receiving appropriate treatment were more likely
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Figure 1 Flow diagram depicting bacterial pneumonia patients admitted from the emergency department. HCAP: healthcare-associated
pneumonia; CAP: community-acquired pneumonia.

to be infected with Streptococcus pneumoniae, MSSA,
Escherichia coli and Haemophilus influenzae (Table 2).
MRSA, Pseudomonas aeruginosa, Enterobacter species
and Acinetobacter species were more common among
patients receiving inappropriate treatment. MRSA was
the most common pathogen accounting for inappropriate treatment (47.2%) followed by Pseudomonas aeruginosa (27.8%). Tracheal aspirates and bronchoalveolar
lavage specimens were more often used to establish the microbiologic diagnosis among patients receiving inappropriate treatment. There was no difference in the presence of
polymicrobial infection or secondary bacteremia between
groups.
We observed an association between comorbidities
and inappropriate treatment. The median Charlson score
was higher in patients receiving inappropriate treatment
(5 vs. 4, p = 0.090). Neurologic conditions such as dementia and stroke occurred equally between groups
while other chronic diseases, such as chronic obstructive
pulmonary disease (COPD), chronic kidney disease, and
peripheral vascular disease occurred more often in patients
receiving inappropriate treatment. Of the comorbidities
evaluated, those linked to the definition of HCAP correlated with inappropriate treatment (Table 1). For example,
long-term care patients were more than nine times (OR,
9.96; 95% CI, 2.02-49.18) as likely to receive inappropriate
treatment. Patients on chronic dialysis (OR, 5.58; 95% CI,
1.36-22.93) or having received previous antibiotic treatment
(OR, 2.12; 95% CI, 1.18-3.79) were also significantly more
likely to receive inappropriate treatment.
Overall, 129 (49.8%) patients were retrospectively
found to have at least one HCAP risk factor. Patients

having any of the HCAP risk factors were significantly
less likely to receive appropriate antibiotic treatment
compared to patients with no HCAP risk factors (61.2%
versus 83.1%; p < 0.001). Inappropriate antibiotic treatment was not associated with excess mortality (Table 3).
However, hospital length of stay was significantly longer among patients receiving inappropriate treatment.
Similarly, 30-day hospital readmission was statistically
greater among patients who initially received inappropriate treatment.
The results of the logistic regression analyses are shown
in Tables 4 and 5. Admission from a long-term care facility,
antibiotic exposure in the previous 30 days, and COPD
were independently associated with the administration of
inappropriate treatment. A similar analysis using 30-day
hospital readmission as the dependent outcome identified
three independent risk factors for this outcome: antibiotic
exposure in the previous 30 days, presence of peripheral
vascular disease and increasing CURB-65 scores.

Discussion
This retrospective analysis of patients diagnosed and
treated for CAP in the ED reveals that inappropriate
antibiotic treatment is common and primarily due to
the presence of antibiotic-resistant pathogens including MRSA and non-lactose fermenting Gram-negative
bacteria (NLFGNB). We found that almost one half of
the patients treated for CAP in the ED had at least one
risk factor for healthcare-associated infection. Healthcareassociated risk factors, including prior antibiotic exposure
and long-term care residency, were found to be predictors
for inappropriate antibiotic treatment. Our study is unique
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Table 1 Baseline characteristics
Variable

Appropriate initial therapy (n = 187)

Inappropriate initial therapy (n = 72)

P value

Age, yrs:

58.1 ± 17.6

62.0 ± 15.3

0.103

Male, n (%):

109 (58.3)

40 (55.6)

0.690

0.779

Race, n (%):
Caucasian

86 (46.0)

31 (43.1)

African-American

98 (52.4)

40 (55.6)

3 (1.6)

1 (1.4)

CURB65

Other

1.9 ± 1.4

2.1 ± 1.2

0.348

Charlson comorbidity score

4.5 ± 3.3

5.4 ± 1.2

0.090

Coronary artery disease

34 (18.2)

14 (19.4)

0.815

Congestive heart failure

56 (29.9)

31 (43.1)

0.045

Peripheral vascular disease

13 (7.0)

13 (18.1)

0.008

Cerebral vascular accident

18 (9.6)

10 (13.9)

0.322

Coexisting conditions, n (%):

Dementia

4 (2.1)

0 (0.0)

0.578

Chronic obstructive pulmonary disease

93 (49.7)

48 (66.7)

0.014

Cirrhosis

23 (12.3)

6 (8.3)

0.364

Diabetes

57 (30.5)

24 (33.3)

0.657

Chronic kidney disease

20 (10.7)

16 (22.2)

0.016

Underlying malignancy

32 (17.1)

12 (16.7)

0.932

1 (0.5)

0 (0.0)

1.000

36 (19.3)

22 (30.6)

0.051

2 (1.1)

7 (9.7)

0.002

HIV positive
Healthcare-associated risk factors, n (%):
Hospitalized in preceding 90 days
Long-term care resident
Chronic hemodialysis

3 (1.6)

6 (8.3)

0.016

Immunocompromised

38 (20.3)

17 (23.6)

0.562

Previous antibiotics

43 (23.0)

28 (38.9)

0.010

0.7 ± 0.9

1.1 ± 1.0

<0.001

Number of healthcare risk factors:
Healthcare-associated infection:

79 (42.2)

50 (69.4)

<0.001

ICU admission, n (%):

52 (27.8)

29 (40.3)

0.052

None

142 (75.9)

51 (70.8)

0.630

Intubation/mechanical ventilation

39 (20.9)

19 (26.4)

6 (3.2)

2 (2.8)

110 (58.8)

45 (62.5)

Respiratory failure, n (%):

Mask ventilation
Hypotension, n (%):

0.589

Values are expressed as mean ± SD. CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate of 30 breaths per minute or greater, blood
pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older; HIV = human immunodeficiency virus; ICU = intensive care unit.
The Charlson comorbidity score predicts the ten-year mortality for a patient who may have a range of comorbid conditions, such as heart disease, AIDS, or cancer
(a total of 22 conditions).

in showing that prior antibiotic exposure, presumably by
predisposing to inappropriate antibiotic treatment, may also
be associated with subsequent 30-day hospital readmission.
These data add to the growing evidence elucidating
the importance of discriminating between patients with
pneumonia having healthcare-associated risk factors, including prior antibiotic exposure, from those without
such risk factors. In one of the largest studies examining

the epidemiology of pneumonia, approximately onethird of all patients with pneumonia admitted to the
hospital were due to HCAP [9]. Subsequent studies have
also documented that HCAP represents between 30%
and 60% of pneumonias requiring hospitalization in the
US [11,14,18,19], and this trend is also observed in Asia
and Europe [10,12,13,20]. Our study also confirms that
MRSA and NLFGNB are common pathogens in patients
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Table 2 Infection characteristics
Variable

Appropriate initial therapy (n = 187)

Inappropriate initial therapy (n = 72)

P value

46 (24.6)

13 (18.1)

0.041

5 (2.7)

6 (8.3)

Cultures source, n(%):
Blood only
BAL
Sputum

105 (56.1)

34 (47.2)

Tracheal aspirate

31 (16.6)

19 (26.4)

Achromobacter species

0 (0.0)

1 (1.4)

0.278

Acinetobacter species

1 (0.5)

5 (6.9)

0.007

Citrobacter species

1 (0.5)

0 (0.0)

1.000

Enterobacter species

1 (0.5)

6 (8.3)

0.002

Escherichia coli

11 (5.9)

0 (0.0)

0.038

Haemophilus influenzae

36 (19.3)

3 (4.2)

0.002

Klebsiella pneumoniae

7 (3.7)

1 (1.4)

0.450

Legionella species

1 (0.5)

0 (0.0)

1.000

Methicillin-resistant Staphylococcus aureus

0 (0.0)

34 (47.2)

<0.001

36 (19.3)

2 (2.8)

<0.001

Moraxella catarrhalis

5 (2.7)

0 (0.0)

0.326

Proteus species

1 (0.5)

1 (1.4)

0.479

Pseudomonas aeruginosa

0 (0.0)

20 (27.8)

<0.001

Streptococcus pneumoniae

79 (42.2)

3 (4.2)

<0.001

Other Streptococci species

22 (11.8)

3 (4.2)

0.097

Polymicrobial, n (%):

14 (7.5)

5 (6.9)

0.881

Positive blood culture, n (%):

51 (27.3)

17 (23.6)

0.549

Methicillin-susceptible Staphylococcus aureus

BAL bronchoalveolar lavage.

presenting to the hospital with pneumonia having HCAP
risk factors [9,13,14].
The importance of initial antibiotic therapy in patients
admitted to the hospital with pneumonia is suggested by
a recent medico-economic analysis conducted by Oster
et al. [21]. These investigators attempted to identify risk
factors for initial treatment failure in patients with CAP
in non-ICU settings, and to characterize the association
between initial treatment failure and length of stay,
total hospital charges, and mortality. Treatment failure
was associated with higher case fatality (8.5% vs. 3.3%),
longer hospital stays (mean [SD], 10.1 [8.1] days vs.
4.9 [3.3] days), and higher total hospital charges
($37,602 [$71,876] vs. $14,371 [$21,633]) (all comparisons, p < 0.01). An important limitation of their study is

that the role of inappropriate initial antibiotic treatment
was not examined.
The findings from our study also confirm the recent
observation made by Shorr et al. that patients with
pneumonia and healthcare-associated risk factors are
more likely to require 30-day hospital readmission
compared to pneumonia patients without healthcareassociated risk factors [22]. Shorr and coworkers found
that admission from a long-term care residency, prior
antibiotic administration, recent hospitalization, and
immunosuppression were independent predictors for
30-day readmission. However, our study is unique in
focusing on patients diagnosed and treated for presumed CAP in the ED and linking 30-day hospital
readmission to the administration of inappropriate

Table 3 Outcomes
Outcome

Appropriate initial therapy (n = 187)

Inappropriate initial therapy (n = 72)

P value

Hospital mortality, n (%):

13 (7.0)

6 (8.3)

0.702

Hospital length of stay, days*:

7.0 ± 8.9

10.3 ± 12.0

0.017

4.0 [3.0,8.0]

6.95 [4.0,12.45]

23 (12.3)

17 (23.6)

30-day hospital readmission, n(%):
th

th

*Data expressed as mean ± SD and median with 25 and 75 percentiles.

0.024
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Table 4 Multivariate analyses of independent risk factors for inappropriate initial antibiotic treatment*
Variable

Adjusted odds ratio

95% CI

P value

Long-term care resident

9.05

3.93 – 20.84

0.008

Antibiotic exposure in previous 30 days

1.85

1.35 – 2.52

0.049

COPD

2.05

1.52 – 2.78

0.018

*Other covariates not in the table had a p value >0.05 including previous hospitalization, mechanical ventilation or mask ventilation, CURB65 score, Charlson
score, congestive heart failure, peripheral vascular disease, chronic kidney disease, hemodialysis, and ICU admission (Hosmer-Lemeshow goodness-of-fit test,
p = 0.726). ICU = intensive care unit; COPD = chronic obstructive pulmonary disease, CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate
of 30 breaths per minute or greater, blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older.

antibiotic treatment, which in turn was independently
associated with prior antibiotic exposure. Prior antibiotic exposure has been shown to be an important
risk factor for the development of certain types of
pneumonia to include drug-resistant Streptococcus
pneumoniae [23], ventilator-associated pneumonia [24]
and HCAP [13]. The common link among these types
of pneumonia is infection due to antibiotic-resistant
bacteria. The presence of a nexus between physicianprescribed antibiotic therapy (e.g., prior antibiotic
exposure, inappropriate antibiotic treatment) and hospital readmission underscores that modifiable patient
characteristics may play a role as key determinants of
whether a hospitalized patient with pneumonia eventually requires readmission.
There are several important limitations of our study
that should be noted. First, the study was performed at
an academic medical center and the results may not be
generalizable to other institutions, especially those with
a lower incidence of MDR pathogens. The large proportion of pneumonia patients with HCAP risk factors
receiving broad-spectrum antibiotic therapy at our institution underscores this point. However, our findings are
in agreement with those from other investigators supporting their overall validity [9-16,20]. Second, we did
not examine all aspects of medical care that may have
influenced the prescription of inappropriate therapy and
the outcomes of our patient cohort. For example, lack of
physician experience or knowledge regarding the importance of broader empiric antibiotic coverage for patients with pneumonia and healthcare-associated risk
factors could have contributed to our results [25]. Third,
the retrospective nature of this study limits our ability to
infer causality between the identified risk factors and

inappropriate antibiotic therapy. Fourth, we did not
identify the specific causes or indications for the 30-day
readmissions. It is possible that the cause of readmission
in many cases may not have been related to the prior
episode of pneumonia or inappropriate treatment of the
pneumonia. Our analysis found that the presence of
peripheral vascular disease, greater CURB-65 scores, and
prior antibiotic exposure predispose to readmission.
These could all be considered to be markers of greater
co-morbidities or severity of illness accounting for the
readmissions.
Another important limitation of our study is that not
all healthcare-associated risk factors carry the same importance. A US study found recent hospitalization, residency in a long-term care facility, chronic hemodialysis,
and admission to the ICU to be the best predictors of
pneumonia due to an antibiotic-resistant pathogen [26].
These findings are similar to those from a European
study that identified prior hospitalization, residence in a
long-term care setting, and chronic renal failure as predictors of antibiotic resistance in pneumonia [27]. However, a study from South Korea found prior antibiotic
exposure and recent hospitalization to be independent
predictors for antibiotic resistance [28]. Similarly, not all
investigators have found antibiotic resistance and inappropriate therapy to be problematic in patients with
pneumonia and healthcare-associated risk factors [29,30].
Several recent studies suggest adverse outcomes with
broader spectrum therapy of pneumonia [31,32]. This has
resulted in a call to avoid the use of the term HCAP and
instead to refer to certain patients with pneumonia as being at increased risk for antibiotic-resistance due to their
specific risk profile [33]. Moreover, it is important to acknowledge that our study only included culture-positive

Table 5 Multivariate analyses of independent risk factors for 30-day hospital readmission*
Variable

Adjusted odds ratio

95% CI

P value

Antibiotic exposure in previous 30 days

2.12

1.45 – 3.10

0.047

Peripheral vascular disease

3.64

2.27 – 5.84

0.006

CURB 65 (1-point increments)

1.46

1.27 – 1.68

0.007

*Other covariates not in the table had a p value >0.05 including inappropriate initial antibiotic treatment, age, chronic dialysis, intensive care unit admission,
COPD, congestive heart failure, and the Charlson score (Hosmer-Lemeshow goodness-of-fit test, p = 0.431). ICU = intensive care unit; COPD = chronic obstructive
pulmonary disease, CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate of 30 breaths per minute or greater, blood pressure less than
90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older.

Micek et al. BMC Infectious Diseases 2014, 14:61
http://www.biomedcentral.com/1471-2334/14/61

patients. Therefore, our data represent the more severe
end of the CAP/HCAP spectrum. The use of empiric
HCAP regimens do not appear to be justified in culturenegative patients with less severe disease [34].

Conclusions
In conclusion we found that inappropriate therapy for
patients diagnosed and treated for CAP in the ED setting
is relatively common. Patients receiving inappropriate
therapy were significantly more likely to have HCAP
risk factors compared to patients receiving appropriate
therapy, suggesting that the identification of these risk
factors, or recognition of their clinical importance, was
underappreciated in these individuals. The association of
inappropriate therapy with longer hospital lengths of
stay and greater 30-day hospital readmission suggests
that efforts to reduce inappropriate therapy in the ED
would be beneficial. Several investigations have applied
multi-disciplinary approaches to the management of such
patients demonstrating improvements in antibiotic prescription to include more targeted use of antimicrobial
agents [35,36]. Future studies evaluating rapid microbiologic techniques, informatics systems for the timely identification of prior antibiotic exposure, and utility of new
antimicrobial agents are needed to improve the treatment
strategies for patients with pneumonia [37]. In the interim,
clinician identification of risk factors for antimicrobial resistance should be emphasized in patients presenting to the
hospital with pneumonia in order to optimize the balance
between providing appropriate therapy and avoiding unnecessary antibiotic exposure [38].
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